Vanda Pharmaceuticals Inc.  

(Public, NASDAQ:VNDA)   Watch this stock  
Find more results for VNDA
14.61
-0.30 (-2.01%)
After Hours: 14.61 0.00 (0.00%)
Apr 23, 5:09PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.30 - 15.08
52 week 4.63 - 19.25
Open 14.80
Vol / Avg. 963,692.00/1.38M
Mkt cap 494.79M
P/E     -
Div/yield     -
EPS -0.66
Shares 33.87M
Beta 7.30
Inst. own 94%
May 22, 2014
Vanda Pharmaceuticals Inc. Annual Shareholder Meeting - 9:00AM EDT - Add to calendar
May 5, 2014
Q1 2014 Vanda Pharmaceuticals Inc. Earnings Release (Estimated) Add to calendar
Feb 13, 2014
Q4 2013 Vanda Pharmaceuticals Inc. Earnings Conference Call - Webcast
Feb 13, 2014
Q4 2013 Vanda Pharmaceuticals Inc. Earnings Release
Feb 3, 2014
Vanda Pharmaceuticals Inc. Conference Call to discuss FDA Approval of HETLIOZT (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -86.79% -59.79%
Operating margin -87.29% -60.21%
EBITD margin - -54.53%
Return on average assets -20.49% -14.53%
Return on average equity -64.97% -74.98%
Employees 53 -
CDP Score - -

Address

Suite 300E, 2200 Pennsylvania Ave NW
WASHINGTON, DC 20037
United States - Map
+1-202-7343400 (Phone)
+1-202-2961450 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company�s product portfolio includes tasimelteon, a compound for the treatment of circadian rhythm sleep disorders (CRSD), which is in clinical development for Non-24, Fanapt, a compound for the treatment of schizophrenia, the oral formulation of which is being marketed and sold in the United States by Novartis Pharma AG (Novartis), and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist.

Officers and directors

Howard H. Pien Independent Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Mihael H. Polymeropoulos M.D. President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
James Patrick Kelly Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 47
Bio & Compensation  - Reuters
Paolo Baroldi M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Michael F. Cola Independent Director
Age: 54
Bio & Compensation  - Reuters
Richard W. Dugan Independent Director
Age: 71
Bio & Compensation  - Reuters
Steven K. Galson M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Vincent J. Milano Independent Director
Age: 49
Bio & Compensation  - Reuters
H. Thomas Watkins Independent Director
Age: 61
Bio & Compensation  - Reuters